Literature DB >> 19208663

Decreased expression of inhibitor of growth 4 correlated with poor prognosis of hepatocellular carcinoma.

Feng Fang1, Lai-Bang Luo, Yi-Ming Tao, Fan Wu, Lian-Yue Yang.   

Abstract

OBJECTIVE: Inhibitor of growth 4 (ING4) is a candidate tumor suppressor that plays an important role in tumor growth and angiogenesis. Here, we examined the expression of ING4 in hepatocellular carcinoma (HCC) tissues and analyzed its correlation with the progression of HCC.
METHODS: Specimens from 136 HCC patients were determined immunohistochemically for ING4 expression. The correlation of ING4 levels with clinicopathologic variables, prognosis, and metastatic potential was analyzed. Among the 136 cases, 36 paired HCC and paracarcinomatous liver tissue specimens were analyzed for ING4 expression levels by real-time quantitative reverse transcription-PCR and Western blotting. MVD was determined by CD34 immunostaining to test whether it correlated with ING4 protein expression level.
RESULTS: The ING4 mRNA and protein levels were significantly lower in HCC than paracarcinomatous liver tissue from both real-time quantitative reverse transcription-PCR and Western blotting (P = 0.039 and 0.012, respectively). Importantly, the ING4 protein level correlated with the Edmondson-Steiner grade (P = 0.035), vein invasion (P = 0.015), and microvessel density (P = 0.005). Survival and metastasis analysis indicated that HCC patients with lower ING4 expression had poorer overall survival and disease-free survival than those with high expression (P = 0.0001 and 0.0065; respectively). Multivariable Cox regression analysis revealed that the ING4 expression level was an independent factor for prognosis (hazard risk, 9.63; P = 0.001).
CONCLUSIONS: ING4 expression is down-regulated in HCC tissues. ING4 expression level correlates with prognosis and metastatic potential, which suggests that ING4 is a candidate prognostic marker of HCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19208663     DOI: 10.1158/1055-9965.EPI-08-0575

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  24 in total

1.  A dominant mutant allele of the ING4 tumor suppressor found in human cancer cells exacerbates MYC-initiated mouse mammary tumorigenesis.

Authors:  Suwon Kim; Alana L Welm; J Michael Bishop
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

2.  Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer.

Authors:  Coya Tapia; Inti Zlobec; Sandra Schneider; Ergin Kilic; Uwe Güth; Lukas Bubendorf; Suwon Kim
Journal:  Hum Pathol       Date:  2011-02-11       Impact factor: 3.466

3.  ING4 is negatively correlated with microvessel density in colon cancer.

Authors:  Chun Lou; Shixiong Jiang; Xinggang Guo; Xin-shu Dong
Journal:  Tumour Biol       Date:  2012-09-28

4.  Downregulation of inhibitor of growth 3 is correlated with tumorigenesis and progression of hepatocellular carcinoma.

Authors:  Meiling Lu; Fei Chen; Qinwan Wang; Kesheng Wang; Qiuhui Pan; Xin Zhang
Journal:  Oncol Lett       Date:  2012-04-19       Impact factor: 2.967

5.  Tumor suppressor ING4 overexpression contributes to proliferation and invasion inhibition in gastric carcinoma by suppressing the NF-κB signaling pathway.

Authors:  Shijie Li; Tianli Fan; Hongtao Liu; Jiangtao Chen; Changjiang Qin; Xuequn Ren
Journal:  Mol Biol Rep       Date:  2013-09-22       Impact factor: 2.316

6.  Association between the expression of inhibitor of growth family member 4 and the progression of clear cell renal carcinoma.

Authors:  Yuxin Ren; Song Zhao; He Chen; Ying-Mei Fu; Bai Zhao
Journal:  Oncol Lett       Date:  2017-06-21       Impact factor: 2.967

7.  Expression of ING4 is negatively correlated with cellular proliferation and microvessel density in human glioma.

Authors:  Bin Shao; Enzhong Liu
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

8.  Citrullination of inhibitor of growth 4 (ING4) by peptidylarginine deminase 4 (PAD4) disrupts the interaction between ING4 and p53.

Authors:  Qin Guo; Walter Fast
Journal:  J Biol Chem       Date:  2011-03-22       Impact factor: 5.157

Review 9.  INGs are potential drug targets for cancer.

Authors:  Runyun Zhang; Jianhua Jin; Juanjuan Shi; Yongzhong Hou
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-20       Impact factor: 4.553

Review 10.  Inhibitor of growth-4 is a potential target for cancer therapy.

Authors:  Shuping Yuan; Jianhua Jin; Juanjuan Shi; Yongzhong Hou
Journal:  Tumour Biol       Date:  2016-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.